Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7912720 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2HSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL1883389 | 0.77 | LTA4H (0.41) | ALDH1A1MAPTLTA4HGRM5AXL | |
| SCHEMBL14970107 | 0.77 | HRH3 (0.43) | SMN1; SMN2HSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL19061756 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL22333711 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL19001707 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL4619770 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2HSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL24150119 | 0.77 | PKM (0.41) | SMN1; SMN2HSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL14046128 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10NPC1RAB9AALDH1A1 | |
| SCHEMBL24603575 | 0.73 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD17B10NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4190784-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| WO-2021123291-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021110656-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021094312-A1 | PYRROLIDINE AND BICYCLOHETEROARYL CONTAINING OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | WO | disclosed |
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-22 | — | — | US | disclosed |
| WO-2019243528-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243530-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | SMN1; SMN2 103/4885HSD17B10 2463/4885NPC1 1281/4885 |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | SMN1; SMN2 103/4885HSD17B10 2463/4885NPC1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.